Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Best PR guys

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on May 31, 2021 1:21pm

117 Views

Post# 33296647

RE:RE:Best PR guys

It has to be deflection, I think they want to release info on their terms and so he just closed that discussion down. I find it unimaginable that Paul isn't asking Christain how the trial is going every day of the week and twice on Sundays.

SPCEO1 wrote: By this point, we must have several patients in the MTD portion of the study. I find it quite odd that Paul indicated he is not aware of what is going on in an open-label study. Would Gettysburg and other clinics refuse to report info back for a period of time? Would there be some internal procedure to block the CEO from learning the status until a certain amount of data was collected? Is this normal? If not, what is going on? Or is Paul pretending not to know as part of a larger strategy to release the info at a time when it is viewed to be most advantageous to TH? I could imagine that LSA might want to hit the ground with a big bang of both the NASH phase III protocol and an important update on the cancer phase I in a way which they believe will maximize the exposure for TH.

Or, it could be that the cancer news is not good at the moment and they are hoping to gather more data which will change the way things look for the better before reporting anything.

qwerty22 wrote: From back on 10 May on Gettysburg cancer centre Facebook page. I feel like these guys are more excited about the trial than THTX. We should keep an eye on this, they've put out calls for trial patients regularly, I hope it's mostly for THTX's trial.

Looks like 3 sites should be active now.

https://www.facebook.com/GettysburgCancerCenter/

“I’ve been doing clinical cancer research close to 20 years, and in all that time I’ve never seen a phase 1 study receive fast-tracked FDA approval prior to dosing patients.

To have that happen here at Gettysburg Cancer Center with the Theratechnologies study on solid cancer tumors is exciting. We are currently still the only site in the world offering this clinical trial, with two additional U.S. sites opening this month. Still, to bring this cutting-edge technology to Gettysburg first, world-wide, is gratifying to an extreme degree.”

-Terry Burke, Clinical Research Coordinator, GCC

Our innovative trials attract local, regional, national and even international cancer patients. Contact us for more information about available clinical trials: